Jae Seon Kang

Dr. Jae Seon Kang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2009 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
KKKang Min Kim
Kang Min Kim
JLJin Young Lee
Jin Young Lee
CKChun Kyu Kim
Chun Kyu Kim
JKJae Seon Kang
Jae Seon Kang

1 January 2011 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
DKDong Hee Kim
Dong Hee Kim
HKHye Kyung Kim
Hye Kyung Kim
KKKang Min Kim
Kang Min Kim
CKChun Kyu Kim
Chun Kyu Kim
MJMin Ho Jeong
Min Ho Jeong
JKJae Seon Kang
Jae Seon Kang

1 September 2019 in Forensic Science International
Verified
Journal Article
Closed access
DJDaseul Jeong
Daseul Jeong
JKJae Seon Kang
Jae Seon Kang
KKKangmin Kim
Kangmin Kim
Seung-Hoon BaekSeung-Hoon Baek
Seung-Hoon Baek
SCSanggil Choe
Sanggil Choe
JPJae Sung Pyo
Jae Sung Pyo

30 March 2017 in Molecular & Cellular Toxicology
Verified
Journal Article
Closed access
PDF file
SOSeon Ok
Seon Ok
JKJae Seon Kang
Jae Seon Kang
KKKangmin Kim
Kangmin Kim

1 February 2011 in Archives of Pharmacal Research
Verified
Journal Article
Closed access
PDF file
SCSang Mi Choi
Sang Mi Choi
MPMin Hi Park
Min Hi Park
TJTae Sung Jung
Tae Sung Jung
KMKyung Ho Moon
Kyung Ho Moon
KKKang Min Kim
Kang Min Kim
JKJae Seon Kang
Jae Seon Kang

12 December 2022 in Plants
Verified
Journal Article
Open access
PDF file
MKMincheol Kang
Mincheol Kang
SPSeojin Park
Seojin Park
YCYuseong Chung
Yuseong Chung
JLJe-Oh Lim
Je-Oh Lim
JKJae Seon Kang
Jae Seon Kang
JPJun Hong Park
Jun Hong Park
Myelosuppression is a major adverse effect of chemotherapy. With the increasing number of cancer patients worldwide, there is a growing interest in therapeutic approaches that reduce the adverse effects of chemotherapy. Angelica gigas Nakai (AGN) roots have been widely used in oriental medicine to treat blood-related diseases, including cancer. However, the effects of AGN on myelosuppression have not been studied. Here, we investigated the effects of AGN ethanol extract (AGNEX) on cyclophosphamide-induced myelosuppression. AGNEX treatment significantly decreased white blood cell levels while increasing red blood cell and platelet levels in the peripheral blood. It inhibited thymus and spleen atrophy. It also enhanced serum levels of interleukin (IL)-6 and tumor necrosis factor (TNF)-α. qRT-PCR results showed that AGNEX decreased the expression of IL-1b and stem cell factor (SCF) in the bone marrow (BM) while increasing the mRNA expression of IL-3 and IL-6 in the spleen. Although AGNEX did not significantly decrease apoptosis and cell cycle arrest in the BM and splenocytes, AGNEX plays a positive role in cyclophosphamide-induced myelosuppression. AGNEX administration increased BM cells in the femur while decreasing apoptotic BM cells. These findings suggest that AGNEX could be used to treat myelosuppression and as a combination therapy in cancer patients.